69445-45-0 Usage
Chemical structure
1-PHENYL-5-HYDROXYBENZIMIDAZOLE is a benzimidazole derivative with a phenyl group at the 1-position and a hydroxyl group at the 5-position of the benzimidazole ring.
Pharmacological and biological activities
PBI has potential as an anti-cancer and anti-viral agent.
Cancer cell growth inhibition
PBI has been studied for its ability to inhibit the growth of cancer cells.
Drug scaffold
PBI serves as a potential drug scaffold for the development of new anti-cancer agents.
Antiviral potential
PBI has shown promise in inhibiting the replication of certain viruses.
Therapeutic uses
Further research is ongoing to fully understand the range of pharmacological activities and potential therapeutic uses of PBI.
Check Digit Verification of cas no
The CAS Registry Mumber 69445-45-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,9,4,4 and 5 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 69445-45:
(7*6)+(6*9)+(5*4)+(4*4)+(3*5)+(2*4)+(1*5)=160
160 % 10 = 0
So 69445-45-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H10N2O/c16-11-6-7-13-12(8-11)14-9-15(13)10-4-2-1-3-5-10/h1-9,16H
69445-45-0Relevant academic research and scientific papers
Identification of a Novel Oxadiazole Inhibitor of Mammalian Target of Rapamycin
Lim, Sunwoo,Lee, Hyomin,Kim, Euijung,Hur, Wooyoung
, p. 296 - 303 (2020/02/04)
We performed a biochemical screen against mTOR using in-house small molecule library. Two novel, structurally distinct hits were identified. Among them, a novel oxadiazole scaffold compound (2) suppressed the phosphorylation of both S6K1 and Akt1 in HeLa cells. Docking study suggested that 2 is ATP-competitive and shows a pi-pi interaction with Trp2239 and hydrogen bonds with Trp2239 and Thr2245. Through derivatization, a slightly more potent analogue (2a) was identified with IC50 of 9.6 μM. Our study provides a starting point for discovery of novel potent mTOR inhibitors.
